Eugit Therapeutics logo

Eugit Therapeutics

https://www.eugittx.com

Enabling Tissue Targeting of Therapies

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

cell-therapysynthetic-biologytherapeuticsoncologybiotechnology

Total Open and Closed Positions

Total open positions, and positions newly closed since the previous update

Department Headcount Over Time

Open positions per department · top 6 at any point in the window

Newly Opened and Closed Positions

Position Churn Rate

Positions closed within 14 days of opening · a high rate suggests posting instability — duplicates, pulled listings, or roles filled through internal or off-market channels

Time-to-Fill Distribution

Days from open to close · closed positions only

Salary Trend Over Time

Monthly median base salary · USD · annualized · p25/p75 dashed

Salary Range by Department

Employment Type

Technical vs. Non-technical

Open positions · by department

Top Roles by Department

Seniority Mix

Derived from job title keywords

Equity Range by Department

Top Skills

Top Tech Stacks

Skills Trend

Change in share of postings · recent 3 months vs. prior 3 months

Tech Stack Evolution

Positions opened per month · top 5 technologies